Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine

  • Ziemba A
  • Hayes E
  • Freeman B
  • et al.
N/ACitations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Myelodysplastic syndromes (MDSs) represent a group of incurable stem-cell malignancies which are predominantly treated by supportive care. Epigenetic silencing through promoter methylation of a number of genes is present in poor-risk subtypes of MDS and often predicts transformation to acute myelogenous leukemia (AML). Azacitidine and decitabine, two FDA-approved DNA methyltransferase (DNMT) inhibitors, are able to improve overall response although their oral bioavailability complicates their clinical use. This study evaluated -triacetyl-5-azacitidine (TAC) as a potential prodrug for azacitidine. The prodrug demonstrated significant pharmacokinetic improvements in bioavailability, solubility, and stability over the parent compound. In vivo analyses indicated a lack of general toxicity coupled with significantly improved survival. Pharmacodynamic analyses confirmed its ability to suppress global methylation in vivo. These data indicate that esterified nucleoside derivatives may be effective prodrugs for azacitidine and encourages further investigation of TAC into its metabolism, activity, and possible clinical evaluation.

Cite

CITATION STYLE

APA

Ziemba, A., Hayes, E., Freeman, B. B., Ye, T., & Pizzorno, G. (2011). Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine. Chemotherapy Research and Practice, 2011, 1–9. https://doi.org/10.1155/2011/965826

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free